论文部分内容阅读
加《医学邮报》第17卷第13期(1981年)报道旧金山消息:一种胰腺癌的敏感标记物可有助于鉴别恶性和良性病变的诊断工作。波士顿的马州综合医院的波多尔斯凯(DK Podolsky)医生发现,在鉴别恶性胰腺疾病时,血清半乳糖转移同功酶Ⅱ(GT-Ⅱ)较CEA方法更准确,特别是与摄影技术联合使用时更利于诊断。波多尔斯凯在美国医生协会上称,患胃肠道恶性病的病人中75％有特异性GT-Ⅱ同功酶,但是正常对照组和非恶性病人中只有2％显示出该酶。与GT-Ⅱ相关的只有乳糜泻病人除外,65％的乳糜泻病人在其血清中也显示出GT-Ⅱ。对疑有胰腺疾病的270名病人的血清
Plus, Medical Post, Vol. 17, No. 13, (1981), reports from San Francisco: A sensitive marker of pancreatic cancer can help identify the diagnosis of malignant and benign lesions. Dr. DK Podolsky of the Massachusetts General Hospital in Boston found that serum galactose transfer isoenzyme II (GT-II) is more accurate than the CEA method in the differential diagnosis of malignant pancreatic diseases, especially in combination with photographic techniques. When used more conducive to diagnosis. Podolsky said at the American Medical Association that 75% of patients with gastrointestinal malignancy have specific GT-II isoenzymes, but only 2% of normal and non-malignant patients show the enzyme. Of the patients associated with GT-II except celiac disease, 65% of patients with celiac disease also showed GT-II in their serum. Serum for 270 patients suspected of having pancreatic disease